Pub Date : 2026-01-15DOI: 10.1016/s0140-6736(26)00048-6
Chen Z, Yang F, Jiang Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet 2025; 406: 2078–88—In this Article, the appendix has been replaced and the affiliations have been updated. These corrections have been made to the online version as of Jan 15, 2026.
{"title":"Department of Error","authors":"","doi":"10.1016/s0140-6736(26)00048-6","DOIUrl":"https://doi.org/10.1016/s0140-6736(26)00048-6","url":null,"abstract":"<em>Chen Z, Yang F, Jiang Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.</em> Lancet <em>2025; <strong>406:</strong> 2078–88</em>—In this Article, the appendix has been replaced and the affiliations have been updated. These corrections have been made to the online version as of Jan 15, 2026.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/s0140-6736(25)02105-1
Michael A Nauck, Katherine R Tuttle, Matthias H Tschöp, Matthias Blüher
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure. These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure. Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis. Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience. Dual (ie, GLP-1–glucagon and GLP-1–amylin) and triple (ie, GIP–GLP-1–glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss. However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability.
{"title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","authors":"Michael A Nauck, Katherine R Tuttle, Matthias H Tschöp, Matthias Blüher","doi":"10.1016/s0140-6736(25)02105-1","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)02105-1","url":null,"abstract":"GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure. These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure. Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis. Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience. Dual (ie, GLP-1–glucagon and GLP-1–amylin) and triple (ie, GIP–GLP-1–glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss. However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"267 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/s0140-6736(25)02069-0
Derick Kimathi, Aitana Juan-Giner, Ndeye S Bob, Benedict Orindi, Maria L Namulwana, Antoine Diatta, Stanley Cheruiyot, Gamou Fall, Moussa Dia, Mainga M Hamaluba, Dan Nyehangane, Henry K Karanja, John N Gitonga, Daisy Mugo, Donwilliams O Omuoyo, Mwatasa Hussein, Elizaphan Oloo, Naomi Kamau, Jackline Wafula, Josephine Bendera, Namanya Silvester, James Mwavita, Musiimenta Joshua, Jane M Thuranira, Collins Agababyona, Caroline Ngetsa, Nalusaji Aisha, Felix Moki, Titus Buluku, Marianne Munene, Juliet Mwanga-Amumpaire, Julius Lutwama, John Kayiwa, Eunice Kamaara, Alan D Barrett, Pontiano Kaleebu, Philip Bejon, Amadou A Sall, Rebecca F Grais, George M Warimwe
{"title":"Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial","authors":"Derick Kimathi, Aitana Juan-Giner, Ndeye S Bob, Benedict Orindi, Maria L Namulwana, Antoine Diatta, Stanley Cheruiyot, Gamou Fall, Moussa Dia, Mainga M Hamaluba, Dan Nyehangane, Henry K Karanja, John N Gitonga, Daisy Mugo, Donwilliams O Omuoyo, Mwatasa Hussein, Elizaphan Oloo, Naomi Kamau, Jackline Wafula, Josephine Bendera, Namanya Silvester, James Mwavita, Musiimenta Joshua, Jane M Thuranira, Collins Agababyona, Caroline Ngetsa, Nalusaji Aisha, Felix Moki, Titus Buluku, Marianne Munene, Juliet Mwanga-Amumpaire, Julius Lutwama, John Kayiwa, Eunice Kamaara, Alan D Barrett, Pontiano Kaleebu, Philip Bejon, Amadou A Sall, Rebecca F Grais, George M Warimwe","doi":"10.1016/s0140-6736(25)02069-0","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)02069-0","url":null,"abstract":"","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"83 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145961807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/s0140-6736(25)02219-6
Ulf Ekelund, Jakob Tarp, Ding Ding, Miguel Adriano Sanchez-Lastra, Knut Eirik Dalene, Sigmund A Anderssen, Jostein Steene-Johannessen, Bjorge H Hansen, Bente Morseth, Laila A Hopstock, Edvard Sagelv, Peter Nordström, Anna Nordström, Maria Hagströmer, Ing-Mari Dohrn, Keith M Diaz, Steven Hooker, Virginia J Howard, I-Min Lee, Morten W Fagerland
{"title":"Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies","authors":"Ulf Ekelund, Jakob Tarp, Ding Ding, Miguel Adriano Sanchez-Lastra, Knut Eirik Dalene, Sigmund A Anderssen, Jostein Steene-Johannessen, Bjorge H Hansen, Bente Morseth, Laila A Hopstock, Edvard Sagelv, Peter Nordström, Anna Nordström, Maria Hagströmer, Ing-Mari Dohrn, Keith M Diaz, Steven Hooker, Virginia J Howard, I-Min Lee, Morten W Fagerland","doi":"10.1016/s0140-6736(25)02219-6","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)02219-6","url":null,"abstract":"","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145962416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/s0140-6736(25)02364-5
Lance Turtle
{"title":"Yellow fever vaccine minimum fractional dosing does not extend to infants","authors":"Lance Turtle","doi":"10.1016/s0140-6736(25)02364-5","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)02364-5","url":null,"abstract":"","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145962460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1016/s0140-6736(25)01912-9
Matthew Whitaker PhD, Joshua Elliott MSc, Ines Gerard-Ursin MSc, Prof Graham S Cooke PhD, Prof Christl A Donnelly ScD, Prof Helen Ward PhD, Prof Paul Elliott PhD, Prof Marc Chadeau-Hyam PhD
Despite highly effective vaccines against SARS-CoV-2, COVID-19 vaccine hesitancy persisted in some populations in England during the pandemic, with rates and motivations for hesitancy varying by demographic group. Addressing the drivers of vaccine hesitancy through targeted interventions in hesitant groups is a public health priority for better and more rapid control of disease spread. We aimed to characterise the determinants and subtypes of vaccine hesitancy and identify more persistent forms of hesitancy via analysis of vaccine uptake in a large cross-sectional cohort with linked National Health Service (NHS) data.
{"title":"Profiling vaccine attitudes and subsequent uptake in 1·1 million people in England: a nationwide cohort study","authors":"Matthew Whitaker PhD, Joshua Elliott MSc, Ines Gerard-Ursin MSc, Prof Graham S Cooke PhD, Prof Christl A Donnelly ScD, Prof Helen Ward PhD, Prof Paul Elliott PhD, Prof Marc Chadeau-Hyam PhD","doi":"10.1016/s0140-6736(25)01912-9","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)01912-9","url":null,"abstract":"Despite highly effective vaccines against SARS-CoV-2, COVID-19 vaccine hesitancy persisted in some populations in England during the pandemic, with rates and motivations for hesitancy varying by demographic group. Addressing the drivers of vaccine hesitancy through targeted interventions in hesitant groups is a public health priority for better and more rapid control of disease spread. We aimed to characterise the determinants and subtypes of vaccine hesitancy and identify more persistent forms of hesitancy via analysis of vaccine uptake in a large cross-sectional cohort with linked National Health Service (NHS) data.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145956977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：